Chronic
obstructive pulmonary disease (COPD) is an important health problem and an
increasing cause of morbidity and mortality worldwide. Currently, COPD is
considered a multisystem disease. Although it primarily affects the lungs, structural
and functional changes occur in other organs due to systemic inflammation. It
is stated that in patients with COPD, airway and systemic inflammatory markers
are increased and that these markers are high are associated with a faster
decline in lung functions. In recent years, numerous articles have been
published on the discovery and evaluation of biomarkers in COPD. Many markers
have also been studied to accurately assess COPD exacerbations and provide
effective treatment. However, based on the evidence from published studies, a
single molecule has not been adequately validated for broad clinical use.
Keywords: Chronic obstructive pulmonary disease, Biomarkers, Exacerbation, Therapy.
